US Patent 9631026 Antibodies that specifically bind to TIM3
Patent 9631026 was granted and assigned to Cellerant Therapeutics on April, 2017 by the United States Patent and Trademark Office.
All edits
Edits on 6 Dec, 2023
Golden AI
Edits made to:
Article (+245 characters)
Article
Patent abstract
Provided herein are antibodies specific for TIM3 that can be used to detect cancer cells, in particular, cancer stem cells. The antibodies can also be used in therapeutic compositions for treating cancer and reducing inflammation.
Edits on 30 Sep, 2023
Golden AI
Edits made to:
Infobox (+2 properties)
Infobox
Patent Inventor Names
Holger Karsunky0
Ying-Ping Jiang0
Edits on 2 Aug, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 26 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 24 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 09631026 Antibodies that specifically bind to TIM3 US Patent 9631026 Antibodies that specifically bind to TIM3
Infobox
Patent Number
096310260
Patent Number
96310260
Edits on 24 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
096310260
Date of Patent
April 25, 2017
0Patent Application Number
144580530
Date Filed
August 12, 2014
0Official Website
Patent Primary Examiner
Edits on 15 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 11 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 09631026 Antibodies that specifically bind to TIM3
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
09631026
Date of patent
April 25, 2017
Patent application number
14458053
Date Filed
August 12, 2014
Patent primary examiner
Find more entities like US Patent 9631026 Antibodies that specifically bind to TIM3
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.